글로벌 경화증(전신 경화증) 치료 시장 – 2028년까지의 산업 동향 및 예측

경화증(전신 경화증) 치료 시장의 시장 분석 및 통찰력

경화증(전신 경화증) 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에 언급된 예측 기간 동안 시장이 6.2%의 CAGR로 성장할 것이라고 분석합니다.

전신성 경화증은 피부 경화, 여러 장기 자극으로 대표되는 만성 자가면역 질환의 한 유형이며, 이 질환에서 가장 흔한 증상은 피부가 두꺼워지는 것입니다. 이 질환의 정확한 원인은 밝혀지지 않았지만 신체에서 콜라겐이 과도하게 생성되는 것으로 알려져 있습니다.

질병에 대한 인식과 이용 가능한 치료 옵션과 관련된 정부 이니셔티브와 프로그램의 수가 빠르게 증가하는 것은 경화증(전신 경화증) 치료 시장의 성장과 수요를 강화하는 필수 요인 중 하나입니다. 게다가, 지속적인 기술 발전도 2021년에서 2028년까지의 예측 기간 동안 글로벌 시장이 성장하는 데 기여하고 있습니다. 또한 경화증의 발병률과 검진율이 증가하고 가처분 소득이 증가함에 따라 시장 성장도 촉진되고 있습니다. 마찬가지로, 인구 중 예방 건강 관리에 대한 인식이 크게 증가함에 따라 위에서 언급한 예측 기간 동안 시장 성장도 증가합니다. 전신 경화증 치료 확대를 위한 연구 개발에 대한 투자가 증가함에 따라 경화증(전신 경화증) 치료 시장이 더욱 확대되고 2021년에서 2028년까지의 예측 기간 동안 시장에 상당한 성장 기회가 제공될 것입니다.

그러나 이 질병에 대한 특정 치료법이 부족하고 질병의 증상에 대한 치료 옵션만 존재하기 때문에 경피증(전신 경화증) 치료 시장 성장은 억제될 가능성이 크다. 질병의 진단 및 기원이 여전히 생소하기 때문에 의사들이 증상 완화를 위한 약물을 선택하는 것이 더욱 복잡해지고 있다. 각 경피증 사례가 다르기 때문에 경피증(전신 경화증) 치료 시장 성장에 도전할 가능성이 있기 때문이다.

This scleroderma (systemic sclerosis) treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on scleroderma (systemic sclerosis) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Scleroderma (Systemic Sclerosis) Treatment Market Scope and Market Size

Scleroderma (systemic sclerosis) treatment market is segmented on the basis of type, indication and therapeutics. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of type, the scleroderma (systemic sclerosis) treatment market is segmented into limited and diffuse.
• Based on indication, the scleroderma (systemic sclerosis) treatment market is segmented into systemic and localized.
• The therapeutics segment of the scleroderma (systemic sclerosis) treatment market is segmented into immunosuppressant, calcium-channel blockers, endothelin receptor antagonists, pde-5 inhibitors, prostacyclin analogues and ACE inhibitors.

Scleroderma (Systemic Sclerosis) Treatment Market Country Level Analysis

Scleroderma (systemic sclerosis) treatment market is analyzed and market size insights and trends are provided by country, type, indication and therapeutics as referenced above.

The countries covered in the scleroderma (systemic sclerosis) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

North America region leads the scleroderma (systemic sclerosis) treatment market owing to the newly developed immunosuppressant along with growing favorable reimbursement scenario in this particular region.

The country section of the scleroderma (systemic sclerosis) treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Scleroderma (systemic sclerosis) treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for scleroderma (systemic sclerosis) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the scleroderma (systemic sclerosis) treatment market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Scleroderma (Systemic Sclerosis) treatment Market Share Analysis

Scleroderma (systemic sclerosis) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to scleroderma (systemic sclerosis) treatment market.

The major players covered in the scleroderma (systemic sclerosis) treatment market report are Actelion Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, BoehringerIngelheim International GmbH, Allergan, GlaxoSmithKline plc., Biogen, Novartis AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, CELGENE CORPORATION, ONO PHARMACEUTICAL CO. LTD., Aspen Holdings, H.A.C. PHARMA, Pfizer Inc., Eli Lilly and Company, Bayer AG, Argentis Pharmaceuticals, LLC., Inventiva, Amgen Inc., Corbus Pharmaceuticals Holdings, Inc., Sanofi  and Cumberland Pharmaceuticals Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-27378